Latest Revenue Generation News

Infotrust has agreed to sell its Cloud & Communications segment, Nexgen, to Aussie Broadband for $50 million, marking a decisive pivot towards cyber security. The move prompts withdrawal of FY26 earnings guidance as the company reshapes its future.

Aurora Labs reported a 15% revenue decline and a 12% increase in net loss for H1 2026, yet marked a strategic breakthrough with its first defence propulsion order and a successful $5.5 million capital raise.

Cyclopharm Limited is rapidly scaling its US presence for Technegas®, securing new contracts across federal institutions and major health networks in four key regions. The company aims for up to 300 installations by late 2026, boosting recurring revenue streams.

Tlou Energy has commissioned its Kala Data Centre in Botswana, marking the first commercial revenue from its Coal Bed Methane gas resources and validating its integrated gas-to-power strategy.

Enero Group’s half-year results reveal a 6.3% revenue decline but a striking 119% surge in adjusted profit, alongside strategic leadership changes and a steady dividend.

Robex Resources has officially reached commercial production at its Kiniero Gold Project in Guinea, marked by a significant first shipment of over 6,300 ounces of gold. This milestone sets the stage for the company’s strategic growth and upcoming merger plans.

AMP Limited's FY25 Data Pack highlights steady earnings with an underlying NPAT of $285 million, supported by strong Platforms net cashflows and a stable capital position. The report offers a detailed breakdown of business unit performance, costs, and market share.

Viva Leisure has reported a robust half-year performance with underlying NPAT up 46.8% and revenue climbing to $116.5 million, driven by strong organic membership growth and a booming technology segment.

Kaiser Reef has transformed the Union Hill waste dumps at its Maldon Gold Project into a significant low-grade gold stockpile, supporting profitable processing at Porcupine Flat through 2030. The company also announced new management appointments and ongoing exploration initiatives.

Rhythm Biosciences has taken a significant step toward commercialising its ColoSTAT blood test for colorectal cancer by enrolling the first physician in its Access Program, marking the transition from clinical trials to routine clinical use.

EVE Health Group has officially launched Libbo™, an oral dissolving film for erectile dysfunction, alongside a new digital platform aimed at improving men’s health access and education across Australia.

Memphasys Limited has secured Therapeutic Goods Administration approval for its Felix™ System two months ahead of schedule, enabling immediate commercial sales and clinical use in Australia.